{"id":7518,"date":"2025-05-23T09:15:00","date_gmt":"2025-05-23T07:15:00","guid":{"rendered":"https:\/\/nanexa.com\/mfn_news\/samtliga-prover-analyserade-fran-30-mg-dosgruppen-i-nex-22-fas-i-studien\/"},"modified":"2025-05-23T09:15:00","modified_gmt":"2025-05-23T07:15:00","slug":"samtliga-prover-analyserade-fran-30-mg-dosgruppen-i-nex-22-fas-i-studien","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/samtliga-prover-analyserade-fran-30-mg-dosgruppen-i-nex-22-fas-i-studien\/","title":{"rendered":"Samtliga prover analyserade fr\u00e5n 30 mg-dosgruppen i NEX-22 fas I-studien"},"content":{"rendered":"<div class=\"mfn-preamble\">\n<p><strong>Nanexa meddelar idag att samtliga farmakokinetiska (PK) prover fr\u00e5n den sista dosgruppen, 30 mg, i fas I-studien f\u00f6r NEX-22 nu har analyserats. Resultaten visar en \u00f6kad exponering i linje med dos\u00f6kningen och demonstrerar fortsatt en kontrollerad och f\u00f6rl\u00e4ngd fris\u00e4ttning av liraglutid, vilket st\u00f6der en enm\u00e5nadsdep\u00e5 av liraglutid.<\/strong><\/p>\n<\/div>\n<div class=\"mfn-body\">\n<p>\u201dNEX-22 studien i sin helhet kommer att presenteras p\u00e5 vetenskapliga kongresser, d\u00e4r deltagande p\u00e5 ADA (American Diabetes Association) i juni \u00e4r en av h\u00f6jdpunkterna\u201d, s\u00e4ger David Westberg, vd Nanexa. \u201dResultaten st\u00e4rker oss ocks\u00e5 i v\u00e5ra diskussioner med potentiella partnerbolag f\u00f6r NEX-22 projektet.\u201d.<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-contacts mfn-2376405b3437\">\n<p><strong class=\"mfn-heading-1\">F\u00f6r mer information kontakta:<\/strong><\/p>\n<hr \/>\n<p>David Westberg \u2013 vd, Nanexa AB (publ)\u00a0<br \/>Telefon: 0709-42 83 03<br \/>E-post:\u00a0<a href=\"mailto:david.westberg@nanexa.se\" rel=\"noopener\" target=\"_blank\">david.westberg@nanexa.se<\/a><br \/><a href=\"http:\/\/www.nanexa.com\" rel=\"noopener\" target=\"_blank\">www.nanexa.com<\/a><\/p>\n<p>Bolagets Certified Adviser \u00e4r DNB Carnegie Investment Bank AB (publ).<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-about mfn-c9ba281e2dde\">\n<p><strong class=\"mfn-heading-1\">Om Nanexa AB (publ)<\/strong><\/p>\n<hr \/>\n<p>Nanexa \u00e4r ett l\u00e4kemedelsbolag som utvecklar injicerbara l\u00e4kemedel baserade p\u00e5 det patenterade och innovativa drug delivery-systemet PharmaShell\u00ae \u2013 ett system som m\u00f6jligg\u00f6r n\u00e4sta generations l\u00e5ngverkande injicerbara l\u00e4kemedel med h\u00f6g drug load, tillverkade med atomlagerprecision. Nanexa utvecklar egna produkter och har dessutom samarbetsavtal med flera l\u00e4kemedelsbolag, d\u00e4ribland Novo Nordisk och AstraZeneca.<\/p>\n<p>Nanexas aktie \u00e4r noterad p\u00e5 Nasdaq First North Growth Market i Stockholm (NANEXA).<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-general\">\n<p><strong class=\"mfn-heading-1\">Bifogade filer<\/strong><\/p>\n<hr \/>\n<p><a class=\"mfn-generated mfn-primary\" href=\"https:\/\/storage.mfn.se\/67fe2ce2-f8b6-4017-ba1b-548c0a12e241\/samtliga-prover-analyserade-fran-30-mg-dosgruppen-i-nex-22-fas-i-studien.pdf\" rel=\"noopener\" target=\"_blank\">Samtliga prover analyserade fr\u00e5n 30 mg-dosgruppen i NEX-22 fas I-studien<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Nanexa meddelar idag att samtliga farmakokinetiska (PK) prover fr\u00e5n den sista dosgruppen, 30 mg, i fas I-studien f\u00f6r NEX-22 nu har analyserats. Resultaten visar en \u00f6kad exponering i linje med dos\u00f6kningen och demonstrerar fortsatt en kontrollerad och f\u00f6rl\u00e4ngd fris\u00e4ttning av liraglutid, vilket st\u00f6der en enm\u00e5nadsdep\u00e5 av liraglutid.<\/p>\n","protected":false},"template":"","class_list":["post-7518","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn-ext-nq_sv","mfn-news-tag-mfn-ext-nq-company-announcement_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-ci-other_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Samtliga prover analyserade fr\u00e5n 30 mg-dosgruppen i NEX-22 fas I-studien - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/samtliga-prover-analyserade-fran-30-mg-dosgruppen-i-nex-22-fas-i-studien\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Samtliga prover analyserade fr\u00e5n 30 mg-dosgruppen i NEX-22 fas I-studien - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Nanexa meddelar idag att samtliga farmakokinetiska (PK) prover fr\u00e5n den sista dosgruppen, 30 mg, i fas I-studien f\u00f6r NEX-22 nu har analyserats. Resultaten visar en \u00f6kad exponering i linje med dos\u00f6kningen och demonstrerar fortsatt en kontrollerad och f\u00f6rl\u00e4ngd fris\u00e4ttning av liraglutid, vilket st\u00f6der en enm\u00e5nadsdep\u00e5 av liraglutid.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/samtliga-prover-analyserade-fran-30-mg-dosgruppen-i-nex-22-fas-i-studien\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/samtliga-prover-analyserade-fran-30-mg-dosgruppen-i-nex-22-fas-i-studien\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/samtliga-prover-analyserade-fran-30-mg-dosgruppen-i-nex-22-fas-i-studien\\\/\",\"name\":\"Samtliga prover analyserade fr\u00e5n 30 mg-dosgruppen i NEX-22 fas I-studien - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2025-05-23T07:15:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/samtliga-prover-analyserade-fran-30-mg-dosgruppen-i-nex-22-fas-i-studien\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/samtliga-prover-analyserade-fran-30-mg-dosgruppen-i-nex-22-fas-i-studien\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/samtliga-prover-analyserade-fran-30-mg-dosgruppen-i-nex-22-fas-i-studien\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Samtliga prover analyserade fr\u00e5n 30 mg-dosgruppen i NEX-22 fas I-studien\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Samtliga prover analyserade fr\u00e5n 30 mg-dosgruppen i NEX-22 fas I-studien - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/samtliga-prover-analyserade-fran-30-mg-dosgruppen-i-nex-22-fas-i-studien\/","og_locale":"sv_SE","og_type":"article","og_title":"Samtliga prover analyserade fr\u00e5n 30 mg-dosgruppen i NEX-22 fas I-studien - Nanexa AB","og_description":"Nanexa meddelar idag att samtliga farmakokinetiska (PK) prover fr\u00e5n den sista dosgruppen, 30 mg, i fas I-studien f\u00f6r NEX-22 nu har analyserats. Resultaten visar en \u00f6kad exponering i linje med dos\u00f6kningen och demonstrerar fortsatt en kontrollerad och f\u00f6rl\u00e4ngd fris\u00e4ttning av liraglutid, vilket st\u00f6der en enm\u00e5nadsdep\u00e5 av liraglutid.","og_url":"https:\/\/nanexa.com\/mfn_news\/samtliga-prover-analyserade-fran-30-mg-dosgruppen-i-nex-22-fas-i-studien\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"1 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/samtliga-prover-analyserade-fran-30-mg-dosgruppen-i-nex-22-fas-i-studien\/","url":"https:\/\/nanexa.com\/mfn_news\/samtliga-prover-analyserade-fran-30-mg-dosgruppen-i-nex-22-fas-i-studien\/","name":"Samtliga prover analyserade fr\u00e5n 30 mg-dosgruppen i NEX-22 fas I-studien - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2025-05-23T07:15:00+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/samtliga-prover-analyserade-fran-30-mg-dosgruppen-i-nex-22-fas-i-studien\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/samtliga-prover-analyserade-fran-30-mg-dosgruppen-i-nex-22-fas-i-studien\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/samtliga-prover-analyserade-fran-30-mg-dosgruppen-i-nex-22-fas-i-studien\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Samtliga prover analyserade fr\u00e5n 30 mg-dosgruppen i NEX-22 fas I-studien"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/7518","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=7518"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}